Patents by Inventor Eric J. Hagen
Eric J. Hagen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9845285Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: GrantFiled: December 3, 2015Date of Patent: December 19, 2017Assignees: CymaBay Therapeutics, Inc., DiaTex, Inc.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Patent number: 9770436Abstract: The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3, 4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.Type: GrantFiled: September 21, 2015Date of Patent: September 26, 2017Assignee: EUTHYMICS BIOSCIENCE, INC.Inventors: Eric J. Hagen, Kevin Halloran
-
Publication number: 20160280636Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: ApplicationFiled: December 3, 2015Publication date: September 29, 2016Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Publication number: 20160008324Abstract: The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3, 4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.Type: ApplicationFiled: September 21, 2015Publication date: January 14, 2016Inventors: Eric J. HAGEN, Kevin HALLORAN
-
Patent number: 9233914Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: GrantFiled: February 25, 2015Date of Patent: January 12, 2016Assignees: CYMABAY THERAPEUTICS, INC., DIATEX, INC.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Patent number: 9139521Abstract: The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.Type: GrantFiled: May 31, 2013Date of Patent: September 22, 2015Assignee: EUTHYMICS BIOSCIENCE, INC.Inventors: Eric J. Hagen, Kevin Halloran
-
Publication number: 20150225333Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: ApplicationFiled: February 25, 2015Publication date: August 13, 2015Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Patent number: 8993797Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: GrantFiled: July 10, 2013Date of Patent: March 31, 2015Assignee: Cymabay Therapeutics, Inc.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Patent number: 8765801Abstract: The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.Type: GrantFiled: February 3, 2012Date of Patent: July 1, 2014Assignee: Euthymics Bioscience, Inc.Inventors: Eric J. Hagen, Kevin Halloran
-
Publication number: 20140024852Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: ApplicationFiled: July 10, 2013Publication date: January 23, 2014Applicants: Diatex, Inc., Metabolex, Inc.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Publication number: 20130345279Abstract: The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.Type: ApplicationFiled: May 31, 2013Publication date: December 26, 2013Inventor: ERIC J. HAGEN
-
Patent number: 8507719Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: GrantFiled: May 11, 2012Date of Patent: August 13, 2013Assignees: Metabolex, Inc.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Publication number: 20120232303Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: ApplicationFiled: May 11, 2012Publication date: September 13, 2012Applicants: Diatex, Inc., Metabolex, Inc.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Patent number: 8203019Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: GrantFiled: April 20, 2006Date of Patent: June 19, 2012Assignees: Metabolex, Inc., DiaTex, Inc.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
-
Publication number: 20120136038Abstract: The invention provides polymorphic crystalline forms of acid addition salts of (±)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.Type: ApplicationFiled: February 3, 2012Publication date: May 31, 2012Inventors: Eric J. HAGEN, Kevin Halloran
-
Publication number: 20110294847Abstract: The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.Type: ApplicationFiled: August 10, 2011Publication date: December 1, 2011Inventors: Eric J. Hagen, Kevin Halloran
-
Publication number: 20110275695Abstract: The invention relates to crystalline forms of zotepine hydrochloride, including the crystalline hydrochloride salt of zotepine and two cocrystals of zotepine hydrochloride with benzoic acid. The preparation and characterization of these crystalline forms of zotepine hydrochloride is described. The invention also relates to the therapeutic use of the crystalline forms of zotepine hydrochloride to treat central nervous system disorders and to pharmaceutical compositions containing them.Type: ApplicationFiled: June 11, 2009Publication date: November 10, 2011Applicant: BIONEVIA PHARMACEUTICALS, INC.Inventors: Isabel Kalofonos, Dimitris Kalofonos, William Martin-Doyle, Jason Hanko, Eric J. Hagen
-
Publication number: 20090326245Abstract: The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.Type: ApplicationFiled: April 22, 2009Publication date: December 31, 2009Inventors: Eric J. HAGEN, Kevin Halloran
-
Patent number: 7625918Abstract: Hydrocodone bitartrate forms are disclosed which are useful as analgesic agents either in combination with or as replacements for hydrocodone bitartrate.Type: GrantFiled: March 8, 2006Date of Patent: December 1, 2009Assignee: Noramco, Inc.Inventors: Eric J. Hagen, Aeri Park
-
Publication number: 20080221018Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.Type: ApplicationFiled: April 20, 2006Publication date: September 11, 2008Applicant: METABOLEX, INC.Inventors: Edward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks